

NHAM CONGRESS 2022 PROGRAM (DRAFT 21st March 2022)

Venue: KLCC Convention Centre
Day 1, Friday (3rd June 2022)

Time	Conference Hall 2				
0700 – 0800	<u>Arrhythmia Morning Grand Round</u> Chairpersons: Panelists:				
0800 – 1030	Chairpersons: <u>0800 – 0805</u> Citation for Razali WATHOOTH <u>0805 – 0830</u> Special Lecture 1 Nik Zainal Memorial Lecture - Historical aspect of cardiology and cardiothoracic <u>0830 – 0850</u> Special Lecture-ACC Plenary Lecture (Webinar) <u>0850 – 0910</u> Special Lecture-ESC Plenary Lecture (Webinar) <u>0910-1030</u> Emcee: Opening Ceremony Launching of - NCVD-ACS 2018 to 2019 Launching of Afib Focus Update Launching of MSH-NHAM Consensus Statement (Renal Denervation) FNHAM Convocation				
1030 – 1100	Tea break				
Time	Conference Hall 2	Ballroom 2	Banquet Hall	Room 304 & 405	Room 301
Concurrent Symposia					
1100 – 1215	<u>Symposium 1</u> Atrial Fibrillation 1.0 Chairpersons:	<u>Symposium 2</u> Heart failure 1.0 Chairpersons:	<u>Symposium 3</u> Diabetes Mellitus 1.0 Chairpersons:	NHAM-SCMR Joint Symposium Chairperson:	Training Village

1100 – 1120	1. A Decade Onwards: How do we make sense on choice of OAC in SPAF	1.Cardiac Imaging in heart failure: Diagnosis, Management and Prognostication	1. Diabetes and Heart Failure: How do we manage them?	1. Role of CMR in MINOCA (with CAD) (Virtual)	Moderator:
1120 – 1140	2. Rate or Rhythm in AF: Individualization of Option	2. Personalizing treatment in Heart Failure: Managing heart rate early Servier	2. Minimizing CV risk in diabetic patients	2. Role of CMR in CAD Assessment (Virtual)	Program for Training Village
1140 – 1200	3. Navigating the route to better thrombosis care for AF renal patients Bayer	3. Bending the Curve for Heart Failure: Let's Get it Right from the Start! Novartis	3. IDegAsp - Into the Multiverse of diabetes management Novo Nordisk	3. Arrhythmogenic Cardiomyopathy (Virtual)	
1200 – 1215	Q & A Objectives: Insights into the practical issues in AF management	Q & A Objectives: Review of heart failure management	Q & A Objectives: Revisit of Diabetes and CVD	Q&A Objectives: Review on the roles of CMR	
Time	Conference Hall 2	Ballroom 2	Banquet Hall		
1215 – 1400	<u>Lunch Symposium 1</u> NOVARTIS	<u>Lunch Symposium 2</u> SERVIER	<u>Lunch Symposium 3</u> SANOFI		
1215 – 1230 (Lunch distribution)	Sybrava (Inclisiran): A Bold Way Forward – How Can Innovation Transform The Way We Treat LDL-C in Patients With ASCVD? Chairperson: 1. <u>1230-1400</u> Panel Discussion 1. 2. 3.	Chairpersons: 1. <u>1230-1235</u> Introduction by chairperson <u>1235-1315</u> 1.Angina: More than what meets the eyes. <u>1315-1355</u> 2. Every Beat Matters, and how to maximize each O2 to the heart (Virtual Live)	Optimizing Post-ACS patient outcomes Chairperson: 1. <u>1230-1235</u> Introduction by chairperson <u>1235-1255</u> New paradigms in post-ACS management: bleeding avoidance strategies 1255-1315 Optimizing Dyslipidemia management from Clinical evidence to Clinical practice 1315-1330 All Panel discussion		

		1355-1400 Closing by Chairperson	Objective: - To be updated on the latest management strategies in balancing ischemic vs bleeding risk in ACS patients - To be updated on optimising dyslipidaemia post-ACS with the latest clinical evidence		
Time	Conference Hall 2	Ballroom 2	Banquet Hall	Room 304 & 305	301
1430 - 1545	Symposium 4 Valvular heart disease Chairpersons: 1. Murmur in pregnancy: Recognizing when it's significant 1430 – 1450 1450 – 1510 1510 – 1530 1530 – 1545 Q & A Objectives: How to approach various valvular conditions	Symposium 5 STEMI Chairpersons: 1. Recognising STEMI Equivalents: Fatal Miss 2. Managing STEMI in Non-PCI Centre 3. Multivessels disease with STEMI: Complete or Culprit Q & A Objectives: Recognising MI Equivalents and how to manage STEMI in non-PCI centre	Symposium 6 Dyslipidemia Chairpersons: 1. Dyslipidemia Hypercholesterolemia Astra Zeneca 2. Redefining Considerations in CVD Prevention for High Risk Patients: Perception vs Evidence Viatris 3. PCKSK9 Inhibitor for Post-MI Patients: Why is timing critical? Amgen Q & A Objectives: Discussion on dyslipidemia and relevant issues	Special Symposium 1 Advanced Cardiology Chairperson: 1. Assessment of valvular disease prior to surgical intervention 2. Management of CIED-related endocarditis 3. Intensive cardiac care: Making sense of inotropes and intensive monitoring Q & A Objectives: Discussion on relevant issues for cardiology fellows/cardiologist	Training Village Moderator: Program for Training Village
1545 – 1615	Tea break				

Time	Conference Hall 2	Ballroom 2	Banquet Hall	Room 304 & 305	301
1615 – 1735	<u>Symposium 7</u> Cardiac imaging	<u>Symposium 8</u> Cardiac Arrhythmia 1.0	<u>Symposium 9</u> Hypertension 1.0	<u>Special Symposium 2</u> FOCUS on Peripheral Vascular Disease	Training Village
	Chairpersons:	Chairperson:	Chairpersons:	Chairperson:	Moderator:
1615 – 1635	1. Echocardiogram: What not to be missed in my clinic?	1. Arrhythmia in Athletes: How do we screen and manage?	1. ABC of Managing Hypertension	1. Screening for PAD in clinical practice: Tips and tricks from the expert	Program for Training Village
1635 – 1655	2. Myocardial Perfusion Scan & Cardiac MRI: What is it?	2. Management of EP Emergency: Unstable Tachyarrhythmia	2. BP and CV Risk Reduction: The Relation and Setting the Target Right <i>Viatrix</i>	2. Why do I get calf pain while walking? What to do?	
1655 – 1715	3. CT Scan and Calcium Score: Utilization and Basic of Interpretation	3. Untangle the ECGs in CIED	3. Heterogeneity among beta-blockers: Heart rate and CV Outcomes <i>Menarini</i>	3. Gangrenous toes assessment and management: What can we do?	
1715 – 1735	Q & A	Q & A	Q & A	Q&A	
	Objectives: Discussion on cardiac imaging modalities	Objectives: Discussions on hot topics in cardiology practice including common dilemmas	Objectives: Revisit management of Hypertension	Objectives: Focused review for peripheral disease	
1735 – 1900	Sub-societies meetings				
Time	Conference Hall 2				
1730 - 1900	SERVIER DINNER SYMPOSIUM BY INVITATION				
	Chairperson:				
	rACE to BP Treatment Goals with Single Pill Combination				

Day 2, Saturday (4th June 2022)

Time	Conference Hall 2				
0700 –0800	<u>Cardio-Radio Imaging Morning Grand Round</u> Chairpersons: Panelists:				
Time	Conference Hall 2	Ballroom 2	Banquet Hall	Room 301	Auditorium
Concurrent Symposia					
0800 – 0915	<u>Symposium 10</u> Covid-19 Lecture Series Chairpersons:	<u>Symposium 11</u> NSTE-ACS Chairpersons:	<u>Symposium 12</u> Chronic coronary syndrome Chairpersons:	Training Village Moderator:	Jeopardy (Preliminary and Finale Round) Moderators
0800 – 0820	1. Vaccination & Heart: What do we know till now?	1. Dual Antiplatelet: Bygones?	1. Chest pain: Evaluation in CCS	Program for Training Village	
0820 – 0840	2. Managing cardiac arrhythmias in Covid-19: During and Post	2. Risk stratification in ACS: Who gets the priority	2. Role of imaging in CCS		
0840 – 0900	3. VTE in Covid Pandemic BI	3. CAD with ticagrelor Astra Zeneca	3. Angina and ischemia: Tailoring treatment to the evidence Menarini		
0900 – 0915	Q&A Objectives: Understanding Covid-19 and cardiac related issues	Q & A Objectives: Review of clinically relevant issues in ACS management	Q & A Objectives: Discussions on patients with CCS		
Time	Conference Hall 2	Ballroom 2	Banquet Hall	Concurrent Free Paper	
0915 – 1030	<u>Satellite Symposium 1</u> PFIZER Cardiac Amyloidosis	<u>Satellite Symposium 2</u> MEDTRONIC The Evolution of Renal Denervation: From consensus to clinical practice	<u>Satellite Symposium 3</u> ZUELLIG PHARMA	<u>Free paper 1</u> (Room 307) <u>Heart Failure Research Award</u>	

	Chairperson: <u>0915-0920</u> Introduce by chairperson <u>0920-1005</u> 1. Overview of ATTR Cardiac Amyloidosis – What you need to know <u>1005-1020</u> Q & A	Chairpersons: <u>0915-0920</u> Introduce by chairperson <u>0920-0940</u> 1.Data: The latest updates from the SPYRAL HTHN Program <u>0940-1000</u> 2.Guidance: MY Consensus update and patient selection <u>1000-1020</u> 3.Practice: RDN as the third pillar of treatment for my patients <u>1020-1030</u> Closing by chairperson	Chairperson: <u>0915-0935</u> 1. Review the role of GLP-1 RAs in Managing T2DM <u>0935-0955</u> 2. GLP-1 RAs: Using CVOT Data to Transform Diabetes Care <u>0955-1015</u> 3.GLP1-RAs: Practical and Safety Concerns <u>1015-1030</u> Q&A Session	<i>Supported by an unrestricted educational grant by SERVIER</i> Judges: 1. 2. 3. 4. 5. <u>0930 – 0945</u> HFRA 1: <u>0945 – 1000</u> HFRA 2: <u>1000 – 1015</u> HFRA 3: <u>1015 – 1030</u> HFRA 4: <u>1030 – 1045</u> HFRA 5: <u>1045 – 1100</u> HFRA 6:	
1030 – 1100	Tea break				
Time	Conference Hall 2	Ballroom 2	Banquet Hall	Room 304/305	
Concurrent Symposia					
1100 – 1235	Young Investigator Award	<u>Symposium 13</u> Women's heart	<u>Symposium 14</u> Cardiology in Primary Care 1.0	<u>Symposium 15</u> Cardio-Oncology	
	Chairpersons:	Chairpersons:	Chairpersons:	Chairpersons:	
	Judges:				
1100-1120	1.	1. CAD and Pregnancy: Too High Risk?	1. Biomarkers for Metabolic Syndrome & CVD: Yay or Nay	1. Making the Case for Cardio-Oncology	
	2.				
	3.				
1120-1140	4.	2. Postmenopausal, HRT and Heart: A Revisit	2. Risk scoring in CVD: How and when to use them	2. Stratification pre-oncology treatment: How much is needed?	
	5.				

1140-1200	<u>1105-1120</u> YIA 1	3. Women and Arrhythmia: Unravel the mystery	3. Back to basic: Recognition clinical signs for cardiovascular disease	3. Oncology & Heart: Surveillance and treating the cardiac complications
1200-1220	<u>1120 -1135</u> YIA 2	Q & A	Q & A	Q & A
	<u>1135-1150</u> YIA 3	Objectives: Understanding the uniqueness of female with cardiovascular disease	Objectives: Discussions on topics pertaining to cardiology in primary care	Objectives: Discussions on cardio-oncology issues
	<u>1150-1205</u> YIA 4			
	<u>1205-1220</u> YIA 5			
	<u>1220-1235</u> YIA 6			
Time	Conference Hall 2	Ballroom 2	Banquet Hall	
1245 – 1430	<u>Lunch Symposium 4</u> MENARINI	<u>Lunch Symposium 5</u> BOEHRINGER INGELHEIM	<u>Lunch Symposium 6</u> ASTRA ZENECA	
1245 – 1300 (Lunch distribution)	Anticoagulation in AF - Optimizing Outcomes in Patients with Increased Bleeding Risk Panelist: <u>1300-1305</u> Opening by Chairperson <u>1305-1340</u> Optimizing anticoagulation outcomes through evidence-based dosing <u>1340-1405</u> The AF Patients in Focus: Elderly and renal impaired <u>1405-1430</u> Panel discussion	Acute Care in NOAC Era: The Heart and the Brain Chairpersons: Panel discussion:	DELIVER, DAPA-ACT? DAPA-MI? - Latest Update ACC (Apr 2022) Chairperson: <u>1300–1305</u> Opening and Welcome Remark <u>1305-1320</u> The Tyranny of Heart Failure <u>1320-1325</u> "HFrEF Case Presentation: - Drug Layering by HF Phenotype " <u>1325-1330</u> Panel discussion + Q&A DAPA-CKD - Latest Update ASN (Nov 2021) <u>1330-1345</u> CKD's takeover of Renal Battlefield	

			<u>1345-1350</u> "CKD & T2D Case Presentation - Early initiation" <u>1350-1355</u> Panel discussion + Q&A <u>1355-1400</u> Summary and Closing Remark	
Time	Conference Hall 2	Ballroom 2	Banquet Hall	Room 304/305
Concurrent Symposia				
1430 – 1545	<u>Symposium 16</u> Atrial Fibrillation 2.0 Chairpersons: 1430 – 1450 1. EHRA guidelines - Atrial Fibrillation Pfizer 1450 – 1510 2. ENTRUST-AF PCI trial in context with other NOAC trials in PCI practice Menarini 1510 – 1530 3. Anticoagulation in high-risk patients - A practical approach Pfizer 1530 – 1545 Q & A Objectives: Looking into subjects of AF and embolism	<u>Symposium 17</u> Heart failure 2.0 Chairpersons: 1. HFpEF: Where do we stand now? 2. Act now for early organ protection: Addressing the CRM disease continuum BI 3. Heart Failure with Below Normal Ejection Fraction: Why does it matter? Novartis Q & A Objectives: Discussions on the issues in chronic heart failure management including latest scientific evidence	<u>Symposium 18</u> Hypertension 2.0 Chairpersons: 1. ARB Vs ACEi: Which one? 2. Management of Hypertensive Emergency 3. Resistant Hypertension: What are we missing here? Q & A Objectives: Overview of hypertension management and practical tips from the experts	<u>Symposium 19</u> Cardio-Rehabilitative Medicine Chairpersons: 1. Heart Failure Rehabilitation 2. Home-based Cardiac Rehabilitation 3. Sex After Heart Attack: Safe & How Soon? Q & A Objectives: Educational session for rehabilitative aspect in cardiac patients
1545 – 1615	Tea break			

Time	Conference Hall 2	Ballroom 2	Banquet Hall	Room 304/305
1615 – 1730	<u>Symposium 20</u> NHAM-ESC Joint Symposium Chairpersons: .	<u>Satellite Symposium 4</u> BAYER Evolving cardiovascular risk: Your patient's past, present and present Chairperson: 1. 2. 3.	<u>Satellite Symposium 5</u> NOVO NORDISK Caring the Sweet Heart Chairperson: <u>1615-1630</u> Welcome & Introduction by Chairperson <u>1630-1650</u> 1.Improving Outcomes with GLP-1RA Innovation <u>1650-1710</u> CV Risk Management in T2DM – Is Intensive Glucose Therapy Enough? <u>1710-1725</u> Q & A <u>1725-1730</u> Closing remarks by Chairperson	<u>Symposium 21</u> Cardiac Arrhythmia 2.0 Chairpersons: <u>1615 – 1635</u> 1. Bradyarrhythmia: Implant or Not? <u>1635 – 1655</u> 2. Cardiac arrhythmias in structural heart disease <u>1655 – 1715</u> 3. Arrested and Survived: What's next? <u>1715 – 1730</u> Q & A Objectives: Discussion of management of common arrhythmias in clinical settings
1615 – 1635				
1635 – 1655				
1655 – 1715				
1715 – 1730				
Time				
1800 – 2000	AGM			

Day 3, Sunday (5th June 2022)

Time	Conference Hall 2 & 3		
0700 – 0800	<u>Arrhythmia Grand Round Finale</u> Chairpersons: Panelists: Case Presenter:		
Time	Conference Hall 2 & 3	Ballroom 2	Banquet Hall
0800 – 0915	<u>Symposium 21</u> Cardio-Renal & Pulmonary Chairpersons:	<u>Symposium 22</u> Coffee Talk with President: “Wearables, Patches and IT in Heart Care” Moderator: Keynote Lecture:	<u>Symposium 23</u> Diabetes Mellitus 2.0 Chairpersons:
0800 – 0820	1. Dyspnoea: Is it acute pulmonary embolism?	1. Innovation in AMI Care: Technology to Systems (Virtual)	1. Insulin therapy in era of newer OHA agents
0820 – 0840	2. Cardio-renal syndrome: Egg & Chicken Story	2. Artificial Intelligence (AI) integration into healthcare delivery (Virtual)	2. Approach in managing hyperglycemia in ASCVD
0840 – 0900	3. Cor Pulmonale: How to approach and manage	3. Making sense of Smart Devices in Digitalization of Healthcare	3. Myriads of Fasting Glucose, Post-prandial Glucose & HbA1c
0900 – 0915	Q&A Objectives: Discussions of cardiac disease in relation to renal and pulmonary condition	Panel discussion	Q & A Objectives: Revisit glycemic management of ASVCD patients
Time	Conference Hall 2	Ballroom 2	Banquet Hall
0915 - 1015	<u>Symposium 24</u> Cardio-Palliative Chairpersons:	<u>Satellite Symposium 6</u> BOEHRINGER INGELHEIM Chairperson:	<u>Symposium 25</u> Know-How in Cardiology Chairpersons:

	Palliative Management in End Stage Heart Failure Advance Care Planning in Chronic Cardiac Disease Communicating Prognosis in Cardiac Disease	<u>0915-0920</u> Welcome by Chairperson <u>0920-0945</u> 1. Empagliflozin: Setting the New Standards in HF Treatment <u>0945-1010</u> 2. From Theory to Application: Initiating Empagliflozin in Clinical Practice Panel Discussion <u>1010-1015</u> Closing by chairperson	Interpretation of Holter Interpretation of Stress Test 24 hours ABPM Interpretation
1015 – 1045	Tea break		
Time	Conference Hall 2	Ballroom 2	Banquet Hall
1045 – 1200	<u>Symposium 26</u>	<u>Symposium 27</u>	<u>Symposium 28</u>
	Adult Congenital Heart Disease: From Womb to Adulthood	Updates from ACC	Cardiology in Primary Care 2.0
	Chairpersons:	Chairpersons:	Chairpersons:
1045 – 1105	1. Pulmonary Hypertension: From Diagnosis to Prognosis		1. Top 5 ECGs to look out for in primary care
1105 – 1125	2. Pregnancy in ACHD: From Womb to Birth		2. Heart failure in primary care: How do to manage and monitor progress?
1125 – 1145	3. Cardiac Imaging in A Glimpse for ACHD		3. Syncope: What can I do in primary care?
1145 – 1200	Q & A Objectives: Overview of adult congenital heart disease	Objectives: Sharing sessions of hot topics and recommendations presented during major cardiology conferences	Q & A Objectives: Common issues faced in primary care setting
Time	Conference Hall 2		
1200 – 1300	Closing Ceremony and Prize Presentation		